November 27 - 30, 2018
Loews Miami Beach Hotel
Miami Beach, Florida, USA
Abstract submission deadline: Friday, September 7
Advance registration deadline: Friday, October 19
Tuesday, Nov. 27
Wednesday, Nov. 28
Thursday, Nov. 29
Friday, Nov. 30
Tuesday, Nov. 27
Welcome and Keynote Lectures
Turning the heat up on pancreatic cancer: Lessons on overcoming a “cold” immunologic micro-environmentElizabeth M. Jaffee, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland
Precision CAR T therapyCarl H. June, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA
Opening Reception7-9 p.m.
Wednesday, Nov. 28
Continental Breakfast7-8 a.m.
Plenary Session 1: Microbiome Influences on Cancer Development and Response to TherapySession Chair: Jennifer Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas8-10:30 a.m.
The role of the microbiome in response to cancer therapyJennifer Wargo
The microbiome associations of colon cancerCynthia L. Sears, Johns Hopkins University School of Medicine, Baltimore, Maryland
Leveraging gut microbiota networks to impact tumor immunotherapy*
Lata Jayaraman, Seres Therapeutics, Cambridge, Massachusetts
Bacteroides fragilis toxin-induced epithelial-mesenchymal transition and stem-like phenotype in breast epithelial cells and concomitantly activated Notch1 and βcatenin axes*
Sheetal Parida, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
Microbiota: Key modulator of the tumor microenvironmentRomina Goldszmid, NIH, Bethesda, Maryland
Tumor and host factors regulating anti-tumor immunity and immunotherapy efficacyThomas Gajewski, The University of Chicago, Chicago, Illinois
Plenary Session 2: Tools for Discovery: Systems Biology and High Density AnalyticsSession Chair: Paul G. Thomas, St. Jude Children’s Research Hospital, Memphis, Tennessee11 a.m.-1 p.m.
Hitting the target: T-cell receptors, cross reactivity, and tumorsPaul G. Thomas
Immuno-mass spectrometric identification of serum biomarkers of response and toxicity to pembrolizumab*Milena Music, University of Toronto, Toronto, ON, Canada
Single-cell analysis illuminates dysfunctional CD8+ T cells as a proliferative, dynamically regulated compartment within human melanoma*
Ido Yofe, Weizmann Institute of Science, Rehovot, Israel
Learning the rules of human cancer immunityNir Hacohen, Broad Institute / Massachusetts General Hospital, Charlestown, Massachusetts
Using high dimensional machine assisted analysis for biomarkers detection and guidance of immunotherapy to cancerCarsten Krieg, Medical University of South Carolina, Charleston, South Carolina
Poster Session A / Lunch1-3:30 p.m.
Plenary Session 3: Metabolic Regulation in Tumors: Implications for TherapySession Chair: Matthew G. Vander Heiden, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts3:30-6 p.m.
Metabolic regulation of cell proliferationMatthew G. Vander Heiden
Collagen scavenging alters macrophage phenotype in pancreatic cancer*
Madeleine LaRue, New York University Medical Center, New York, New York
Blockage of AHR activation by IDO/TDO-derived kynurenine restricts cancer immune suppression* Luis Felipe Campesato, Memorial Sloan Kettering Cancer Center, New York, New York
Fueling T cells in inflammation and cancerJeffrey C. Rathmell, Vanderbilt University Medical Center, Nashville, Tennessee
Dinner on Own5:45 p.m.-
Thursday, Nov. 29
Plenary Session 4:
Myeloid and Vascular Programs in Cancer: Key Regulators of Antitumor Immunity
Session Chair: Matthew F. Krummel, University of California San Francisco, San Francisco, California8-10 a.m.
The key role for IRF8+ dendritic cells in cancer immunityMiriam Merad, Icahn School of Medicine at Mount Sinai, New York, New York
Vascular reprogramming for enhancing cancer immunotherapyMichele De Palma, Swiss Federal Institute of Technology, Lausanne, Switzerland
Targeting CD47 as a novel immunotherapy for multiple myeloma*
Jennifer Sun, Washington University in St. Louis, St. Louis, Missouri
Human chimeric antigen receptor (CAR) macrophages for cancer immunotherapy^*Michael Klichinsky, University of Pennsylvania, Philadelphia, Pennsylvania
Imaging a world beyond checkpoints: Classes of immune responses in cancerMatthew F. Krummel
Plenary Session 5:
Novel Checkpoints for Tumor Immunity
Session Chair: Elizabeth M. Jaffee, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland
10:30 a.m.-1 p.m.
Molecular mechanisms of T cell exhaustion and implications for immunotherapy E. John Wherry, University of Pennsylvania, Philadelphia, Pennsylvania
The mechanistic basis of cancer immunotherapyIra Mellman, Cancer Immunology, Genentech, Inc., South San Francisco, California
Lymphatic vessels: Barriers to adaptive immunity in melanoma Amanda Lund, Oregon Health & Science University, Portland, Oregon
Discovery of immune regulators in primary human T cells using genome-wide CRISPR screens*
Julia Carnevale, University of California San Francisco, San Francisco, California
ADU-S100 (MIW815) synergizes with checkpoint blockade to elicit an antitumor CD8+ T-cell response to control distal tumors*
Weiwen Deng, Aduro Biotech, Inc., Berkeley, California
Immune checkpoint blockade in cancer therapy: New insights and opportunities, and prospects for curesJames P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas
Lunch on Own1-2:30 p.m.
Plenary Session 6: New Combinations and BiomarkersSession Chair: Sandra S. McAllister, Harvard Medical School, Boston, Massachusetts2:30-5 p.m.
From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapyPadmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas
Pharmacological and physiological processes that affect response to immunotherapySandra S. McAllister, Harvard Medical School, Boston, Massachusetts
Heterogeneous activation of multiple suppressive pathways by scRNAseq may underscore resistance to PD-1 therapy in metastatic castration-resistant prostate cancer*
Amy Moran, Oregon Health & Science University, Portland, Oregon
Tumor cell-intrinsic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer*
Jinyang Li, University of Pennsylvania, Philadelphia, Pennsylvania
Marker-guided targeted therapy, PARP inhibitors, and novel post-translational modification of PD-L1Mien-Chie Hung, The University of Texas MD Anderson Cancer Center, Houston, Texas
Understanding mechanisms for combination immunotherapyJedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, New York
Poster Session B / Reception5-7 p.m.
Friday, Nov. 30
Continental Breakfast7-8 a.m.
Assessing in vivo mechanisms regulating the therapeutic activity of bi-specific T cell engager (BiTE®) molecules in immune-competent mice expressing a chimeric human/mouse CD3ε receptor^* Brian Belmontes, Amgen Discovery Research, Amgen Inc., Thousand Oaks, California
Development of chimeric forms of IFN-alpha for “on demand” in vivo cancer gene therapy* Nadia Coltella, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy
CD123CAR displays clinical activity in relapsed/refractory (r/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study* Lihua Budde, City of Hope National Medical Center, Duarte, California
A novel NK cell-targeted therapeutic strategy against pancreatic cancer* Kamiya Mehla, University of Nebraska Medical Center, Omaha, NE RNA aptamers specific for tumor-infiltrating myeloid cells* Dimitri Van Simaeys, Sylvester Cancer Center, Miami, Florida
Targeted blockade of FcγRIIB on dendritic cells and macrophages enhances cellular activation and Fc-dependent immune responses* Ryan Molony, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts
A novel immunomodulatory strategy of targeting glycol-immune checkpoints using EAGLE technology to treat cancer* Li Peng, Palleon Pharmaceuticals, Waltham, Massachusetts (not eligible for CME credit)
Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic payloads in metastatic tumors* Adrian Pelin, Ottawa Hospital Research Institute, Ottawa, ON, Canada
Plenary Session 7: Emerging Molecular and Cellular TargetsSession Chair: Lisa M. Coussens, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon10 a.m.-12:30 p.m.
Control of tumor immune suppression by macrophage PI3Kγ regulated pathwaysJudith A. Varner, University of California San Diego, San Diego, California
A novel combination immunotherapy with a vaccine targeting tumor neoepitopes that mediates immune cascade in murine tumor models*
Karin Lee, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
IL-35+ B cells establish immunosuppressive network in pancreatic ductal adenocarcinoma*
Bhalchandra Mirlekar, The Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Dynamic interactions between myeloid and lymphoid cells regulate response to therapy in solid tumorsLisa M. Coussens
Tissue specific immune tolerance promotes tumor-immune escapeNiroshana Anandasabapathy, Weill Cornell Medical College, New York, New York
Repertoire and expression profiles and function of neoantigens-specific T cellsDrew M. Pardoll, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland
Closing Remarks12:30 p.m.
^Not eligible for CME credit
*Short talk from proffered abstracts
Top of page